Persistent Chronic Thrombo-Inflammation in Anti-Glomerular Basement Membrane Disease Despite Immune Complex Removal

Area of Science:

• Nephrology
• Immunology
• Hematology

Background:

• Anti-glomerular basement membrane (anti-GBM) disease is a severe autoimmune condition causing rapid kidney damage.
• Kidney-derived hematopoietic growth factors (HGFs) like thrombopoietin (TPO) stimulate platelet production, worsening thrombosis and inflammation.
• Activated platelets release molecules that promote microvascular dysfunction and extracellular matrix deposition in glomeruli.

Purpose of the Study:

• To investigate if anti-GBM disease stimulates kidney-derived HGFs and pro-inflammatory mediators.
• To determine if immobilized anti-GBM antibodies activate platelets via FcγRIIA, causing chronic platelet activation.

Main Methods:

• Analysis of plasma samples from patients in the GOOD-IDES-01 trial (receiving imlifidase plus standard care) and healthy blood donors.
• Measurement of plasma HGFs, pro-inflammatory markers, platelet activation markers, and platelet-derived products before and after treatment.

Main Results:

• Anti-GBM disease significantly increased plasma pro-inflammatory markers, platelet activation markers, and HGFs (TPO, SCF).
• Plasma TPO levels correlated with anti-GBM antibody titers.
• While imlifidase and standard care reduced TPO and platelet counts, platelet activation markers remained elevated, correlating with platelet-derived products.

Conclusions:

• Circulating HGFs, pro-inflammatory cytokines, and platelet activation markers are key biomarkers for anti-GBM disease activity.
• Chronic platelet activation in anti-GBM disease is independent of anti-GBM antibody integrity.
• Novel therapeutic strategies targeting thrombo-inflammation are necessary for effective management.